[1] Kondo K, Yanishi K, Hayashida R, Shintani S, Shibata R, Murotani K, Ando M, Mizuno M, Fujiwara T, Murohara T, Matoba S; TACT Follow-up Study Investigators. Long-Term Clinical Outcomes Survey of Bone Marrow-Derived Cell Therapy in Critical Limb Ischemia in Japan. Circ J. 2018;82:1168–78.
[2] Slovut DP, Sullivan TM. Critical limb ischemia: medical andsurgical management. Vasc Med. 2008;13(3):281–91.
[3] Hankey GJ, Norman PE, Eikelboom JW. Medica treatment of peripheralarterial disease. JAMA-J AM MED ASSOC. 2006;295(5):547–53.
[4] Neale JPH, Pearson JT, Katare R, Schwenke DO. Ghrelin, MicroRNAs, and critical limb ischemia: Hungering for a novel treatment option. Front Endocrinol (Lausanne). 2017;8:350.
[5] Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg, 2007;45(1): S5–S67.
[6] Annex BH. Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol. 2013;10(7): 387–96.
[7] Li JY, Yang XY, Wang XF, Jia X, Wang ZJ, Deng AP, Bai XL, Zhu L, Li BH, Feng ZB, Li Y, Wang L, Jin S. Siglec–5 is a novel marker of critical limb ischemia in patients with diabetes. Sci Rep. 2017;7(1):11272.
[8]Kirana S, Stratmann B, Prante C, Prohaska W, Koerperich H, Lammers D, et al. Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients. Int J Clin Pract. 2012;66(4):384–93.
[9]Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol. 2004;36(6):961–8.
[10]Muppala S, Frolova E, Xiao R, Krukovets I, Yoon S, Hoppe G, et al. Proangiogenic Properties of Thrombospondin–4. Arterioscler Thromb Vasc Biol. 2015;35(9):1975–86.
[11]Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 1995;12(1):1–21.
[12] Spiliopoulos S, Theodosiadou V, Katsanos K, Kitrou P, Kagadis GC, Siablis D, Karnabatidis D. Long-term clinical outcomes of infrapopliteal drug-eluting stent placement for critical limb ischemia in diabetic patients. J Vasc Interv Radiol 2015;26:1423–30.
[13] Kimura A, Kobayashi Y, Takahashi M, Ohbuchi N, Kitamura H, Nakamura T, Satoh M, Sasaoka T, Hiroi S, Arimura T, et al. MICA gene polymorphism in Takayasu’s arteritis and Buerger’s disease. Int J Cardiol. 1998;66 (Suppl 1): S107‑13; discussion S115.
[14] Sadik NA, Mohamed WA, Ahmed MI. The association of receptor of advanced glycated end products and inflammatory mediators contributes to endothelial dysfunction in a prospective study of acute kidney injury patients with sepsis. Mol Cell Biochem. 2012;359(1–2):73–81.
[15] Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996;348(9024):370–4.
[16] Amann B, Luedemann C, Ratei R, Schmidt-Lucke JA. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant. 2009;18(3):371–80.
[17] Horie T, Onodera R, Akamastu M, Ichikawa Y, Hoshino J, Kaneko E, Iwashita C, Ishida A, Tsukamoto T, Teramukai S, Fukushima M, Kawamura A; Japan Study Group of Peripheral Vascular Regeneration Cell Therapy (JPRCT). Long-term clinical outcomes for patients with lower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells. Atherosclerosis. 2010;208(2):461–6.
[18] Franz RW, Shah KJ, Pin RH, Hankins T, Hartman JF, Wright ML. Autologous bone marrow mononuclear cell implantation therapy is an effective limb salvage strategy for patients with severe peripheral arterial disease. J Vasc Surg. 2015;62(3):673–80.
[19] Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet. 2002;360(9331):427–35.
[20] Matoba S, Tatsumi T, Murohara T, Imaizumi T, Katsuda Y, Ito M, Saito Y, Uemura S, Suzuki H, Fukumoto S, Yamamoto Y, Onodera R, Teramukai S, Fukushima M, Matsubara H; TACT Follow-up Study Investigators. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J. 2008;156(5):1010–8.
[21] Idei N, Soga J, Hata T, Fujii Y, Fujimura N, Mikami S, Maruhashi T, Nishioka K, Hidaka T, Kihara Y, Chowdhury M, Noma K, Taguchi A, Chayama K, Sueda T, Higashi Y. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: A comparison of atherosclerotic peripheral arte- rial disease and Buerger disease. Circ Cardiovasc Interv. 2011;4(1):15–25.
[22] Kondo K, Yanishi K, Hayashida R, Shintani S, Shibata R, Murotani K, Ando M, Mizuno M, Fujiwara T, Murohara T, Matoba S; TACT Follow-up Study Investigators. Long-Term Clinical Outcomes Survey of Bone Marrow-Derived Cell Therapy in Critical Limb Ischemia in Japan. Circ J. 2018;82(4):1168–78.
[23] Guo J, Guo L, Cui S, Tong Z, Dardik A, Gu Y. Autologous bone marrow-derived mononuclear cell therapy in Chinese patients with critical limb ischemia due to thromboangiitis obliterans: 10-year results. Stem Cell Res Ther. 2018;9(1):43.
[24]Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science. 1998;279(5356):1528–30.
[25]Shichinohe H, Yamauchi T, Saito H, Houkin K, Kuroda S. Bone marrow stromal cell transplantation enhances recovery of motor function after lacunar stroke in rats. Acta Neurobiol Exp (Wars). 2013;73(3):354–63.
[26]Wei L, Fraser JL, Lu ZY, Hu X, Yu SP. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis. 2012;46(3):635–45.
[27]Chen J, Venkat P, Zacharek A, Chopp M. Neurorestorative therapy for stroke. Front Hum Neurosci. 2014;8:382.
[28]Pavlichenko N, Sokolova I, Vijde S, Shvedova E, Alexandrov G, Krouglyakov P, et al. Mesenchymal stem cells transplantation could be beneficial for treatment of experimental ischemic stroke in rats. Brain Res. 2008;1233:203–13.
[29]Onteniente B, Polentes J. Regenerative medicine for stroke - are we there yet? Cerebrovasc Dis. 2011;31(6):544–51.
[30]Adams JC. Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol. 2001;17:25–51.
[31]Tymchuk CN, Hartiala J, Patel PI, Mehrabian M, Allayee H. Nonconventional genetic risk factors for cardiovascular disease. Curr Atheroscler Rep. 2006;8(3):184–92.
[32]Forslow A, Liu Z, Sundqvist KG. Receptor communication within the lymphocyte plasma membrane: a role for the thrombospondin family of matricellular proteins. Cell Mol Life Sci. 2007;64(1):66–76.
[33]Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest. 2001;107(8):929–34.
[34]DiPietro LA, Nebgen DR, Polverini PJ. Downregulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesis. J Vasc Res. 1994;31(3):178–85.
[35]Frolova EG, Sopko N, Blech L, Popovic ZB, Li J, Vasanji A, et al. Thrombospondin–4 regulates fibrosis and remodeling of the myocardium in response to pressure overload. FASEB J. 2012;26(6):2363–73.
[36]Frolova EG, Pluskota E, Krukovets I, Burke T, Drumm C, Smith JD, et al. Thrombospondin–4 regulates vascular inflammation and atherogenesis. Circ Res. 2010;107(11):1313–25.
[37]Raman P, Krukovets I, Marinic TE, Bornstein P, Stenina OI. Glycosylation mediates up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin–1, by glucose in vascular smooth muscle cells. J Biol Chem. 2007;282(8):5704–14.
[38]Pluskota E, Stenina OI, Krukovets I, Szpak D, Topol EJ, Plow EF. Mechanism and effect of thrombospondin–4 polymorphisms on neutrophil function. Blood. 2005;106(12):3970–8.
[39]Stenina OI, Desai SY, Krukovets I, Kight K, Janigro D, Topol EJ, et al. Thrombospondin–4 and its variants: expression and differential effects on endothelial cells. Circulation. 2003;108(12):1514–9.
[40]Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest. 2003;111(12):1843–51.
[41]Cui X, Chopp M, Zacharek A, Roberts C, Lu M, Savant-Bhonsale S, et al. Chemokine, vascular and therapeutic effects of combination Simvastatin and BMSC treatment of stroke. Neurobiol Dis. 2009;36(1):35–41.
[42]Xu J, Liu X, Chen J, Zacharek A, Cui X, Savant-Bhonsale S, et al. Simvastatin enhances bone marrow stromal cell differentiation into endothelial cells via notch signaling pathway. Am J Physiol Cell Physiol. 2009;296(3):C535–43.
[43]Deng YB, Ye WB, Hu ZZ, Yan Y, Wang Y, Takon BF, et al. Intravenously administered BMSCs reduce neuronal apoptosis and promote neuronal proliferation through the release of VEGF after stroke in rats. Neurol Res. 2010;32(2):148–56.
[44]Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16(5):585–601.
[45]Kryger ZB, Sisco M, Roy NK, Lu L, Rosenberg D, Mustoe TA. Temporal expression of the transforming growth factor-Beta pathway in the rabbit ear model of wound healing and scarring. J Am Coll Surg. 2007;205(1):78–88.